Free Newsletter
Chemists laid off at GlaxoSmithKline
GlaxoSmithKline's June announcement that it was cutting 350 jobs worldwide is coming to fruition. The company just laid off 22 scientists at its Medicinal Chemistry and Oncology Department in Research Triangle Park, North Carolina.
Already this summer, the company laid off nearly 200 workers, with half in its research department in June and about 90 more from a manufacturing plant in Zebulon. Company spokespeople say its just part of GSK's overall R&D "restructuring" plan to increase research and development and make manufacturing more efficient.
- read more at the News & Observer
- see the Herald Sun story
Related Articles:
Big Pharma's biotech shift means layoffs for chemists
Ailing GlaxSmithKline to axe 350 R&D workers
GSK plant closure begins 5,000 job cuts
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: